Related Experiment Videos
Clinical and bacteriological evaluation of cefoxitin therapy in children
Insights
Cefoxitin is a safe and effective antibiotic for treating bacterial infections in children, excluding meningitis. This study found it well-tolerated with high cure rates for common infections like cellulitis and pneumonia.
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Therapy
- Pharmacology
Background:
- Bacterial infections are a common concern in pediatric populations.
- Parenteral beta-lactam antibiotics are frequently used for treating serious bacterial infections in children.
- Cephamycin antibiotics offer a broad spectrum of activity against various bacterial pathogens.
Purpose of the Study:
- To evaluate the safety and efficacy of cefoxitin in pediatric patients with bacterial infections.
- To assess cefoxitin's tolerability and adverse event profile in children.
- To determine cefoxitin's effectiveness against common pediatric bacterial pathogens.
Main Methods:
- A study involving 26 pediatric patients aged 3 months to 7 years with bacterial infections (excluding meningitis).
- Patients received cefoxitin at doses ranging from 80 to 160 mg/kg per day.
- Clinical outcomes, pathogen identification, and adverse events were monitored.
Main Results:
- The most frequent diagnoses included cellulitis, pneumonia, and bone/joint infections.
- Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pneumoniae were the most common pathogens, all susceptible to cefoxitin.
- All 26 children showed improvement or were cured, with no severe adverse reactions reported.
Conclusions:
- Cefoxitin demonstrated significant safety and efficacy in treating pediatric bacterial infections beyond meningitis.
- The antibiotic was well-tolerated, with minor adverse events like phlebitis and eosinophilia.
- Cefoxitin is a viable therapeutic option for children with susceptible bacterial infections.
Abstract:
Cefoxitin, a parenteral cephamycin beta-lactam antibiotic, was evaluated for safety and efficacy in children with bacterial infections other than meningitis. Twentysix patients between 3 months and 7 years of age were treated with 80 to 160 mg/kg per day. The most common diagnoses were cellulitis (13 patients), pneumonia (5 patients), and bone and joint infection (4 patients). Nine patients were bacteremic. The most frequently recovered pathogens were Staphylococcus aureus (six patients), Haemophilus influenzae (four patients), and Streptococcus pneumoniae (three patients). All organisms were susceptible to cefoxitin. All 26 children were considered improved or cured. No severe adverse reactions were encountered. Phlebitis (4%), eosinophilia (12%), and elevated liver function tests (4%) were associated with therapy. Cefoxitin appears to be a safe, effective, and well-tolerated antibiotic when used in children with susceptible bacterial infections other than meningitis.